BR9710030A - Processo de produção de adenovírus recombinantes processo de purificação de adenovírus recombinantes a partir de um meio biológico preparação viral purificada composição farmacêutica e utilização de iodixanol-5,5'-[(2-Hidroxipropil-1,3-Propanottl)-Bis[N,N'-Bis(2,3-Didroxipropil-2,4,6-Triodo-1,3-Benzenocarboxamida] - Google Patents

Processo de produção de adenovírus recombinantes processo de purificação de adenovírus recombinantes a partir de um meio biológico preparação viral purificada composição farmacêutica e utilização de iodixanol-5,5'-[(2-Hidroxipropil-1,3-Propanottl)-Bis[N,N'-Bis(2,3-Didroxipropil-2,4,6-Triodo-1,3-Benzenocarboxamida]

Info

Publication number: BR9710030A
Authority: BR; Brazil
Prior art keywords: bis; recombinant adenoviruses; propanottl; didroxypropyl; benzenocarboxamide
Prior art date: 1996-07-01

Application number

BR9710030A

Other languages

English (en)

Inventor

Francis Blanches

Jean-Marc Guillaume

Original Assignee

Rhone Poulenc Rorer Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-01

Filing date

1997-06-20

Publication date

1999-08-10

1996-07-01 Priority claimed from FR9608164A external-priority patent/FR2750433B1/fr

1997-06-20 Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa

1999-08-10 Publication of BR9710030A publication Critical patent/BR9710030A/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/20—Anion exchangers for chromatographic processes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Microbiology (AREA)
General Health & Medical Sciences (AREA)
Water Supply & Treatment (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Plant Pathology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BR9710030A 1996-07-01 1997-06-20 Processo de produção de adenovírus recombinantes processo de purificação de adenovírus recombinantes a partir de um meio biológico preparação viral purificada composição farmacêutica e utilização de iodixanol-5,5'-[(2-Hidroxipropil-1,3-Propanottl)-Bis[N,N'-Bis(2,3-Didroxipropil-2,4,6-Triodo-1,3-Benzenocarboxamida] BR9710030A (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR9608164A FR2750433B1 (fr)	1996-07-01	1996-07-01	Procede de production d'adenovirus recombinants
US2666796P	1996-09-25	1996-09-25
PCT/FR1997/001107 WO1998000524A1 (fr)	1996-07-01	1997-06-20	Procede de production d'adenovirus recombinants

Publications (1)

Publication Number	Publication Date
BR9710030A true BR9710030A (pt)	1999-08-10

Family

ID=26232805

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9710030A BR9710030A (pt)	1996-07-01	1997-06-20	Processo de produção de adenovírus recombinantes processo de purificação de adenovírus recombinantes a partir de um meio biológico preparação viral purificada composição farmacêutica e utilização de iodixanol-5,5'-[(2-Hidroxipropil-1,3-Propanottl)-Bis[N,N'-Bis(2,3-Didroxipropil-2,4,6-Triodo-1,3-Benzenocarboxamida]

Country Status (13)

Country	Link
US (3)	US6485958B2 (pt)
EP (1)	EP0944717A1 (pt)
JP (1)	JP2000514290A (pt)
KR (1)	KR20050043996A (pt)
AU (1)	AU3447097A (pt)
BR (1)	BR9710030A (pt)
CA (1)	CA2258158A1 (pt)
CZ (1)	CZ438398A3 (pt)
HU (1)	HU224558B1 (pt)
IL (1)	IL127692A0 (pt)
NO (1)	NO986202L (pt)
SK (1)	SK181098A3 (pt)
WO (1)	WO1998000524A1 (pt)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6143548A (en) *	1995-08-30	2000-11-07	Genzyme Corporation	Chromatographic purification of adeno-associated virus (AAV)
BR9710030A (pt) *	1996-07-01	1999-08-10	Rhone Poulenc Rorer Sa	Processo de produção de adenovírus recombinantes processo de purificação de adenovírus recombinantes a partir de um meio biológico preparação viral purificada composição farmacêutica e utilização de iodixanol-5,5'-[(2-Hidroxipropil-1,3-Propanottl)-Bis[N,N'-Bis(2,3-Didroxipropil-2,4,6-Triodo-1,3-Benzenocarboxamida]
US7732129B1 (en)	1998-12-01	2010-06-08	Crucell Holland B.V.	Method for the production and purification of adenoviral vectors
JP4492826B2 (ja)	1996-11-20	2010-06-30	イントロジェンセラピューティクス，インコーポレイテッド	アデノウイルスベクターの産生および精製のための改良された方法
ES2283032T3 (es)	1996-12-13	2007-10-16	Schering Corporation	Metodos para purificar virus.
US6544769B1 (en) *	1996-12-13	2003-04-08	Schering Corporation	Compostions comprising viruses and methods for concentrating virus preparations
US20080261289A1 (en) *	1996-12-13	2008-10-23	Schering-Plough Corporation	Compositions comprising viruses and methods for concentrating virus preparations
US6146891A (en) *	1997-01-31	2000-11-14	Schering Corporation	Methods for cultivating cells and propagating viruses
US6995006B2 (en)	1997-09-05	2006-02-07	Targeted Genetics Corporation	Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en)	1997-09-05	2003-05-20	Targeted Genetics Corporation	Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6383795B1 (en)	1998-04-22	2002-05-07	Genvec, Inc.	Efficient purification of adenovirus
EP1080218A1 (en) *	1998-05-27	2001-03-07	University of Florida	Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient
AU770672B2 (en) *	1998-05-27	2004-02-26	University Of Florida	Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient
US6689600B1 (en)	1998-11-16	2004-02-10	Introgen Therapeutics, Inc.	Formulation of adenovirus for gene therapy
FR2788064B1 (fr) *	1998-12-31	2003-01-31	Aventis Pharma Sa	Methode de separation de particules virales
PL349074A1 (en) *	1998-12-31	2002-07-01	Aventis Pharma Sa	Method for separating viral particles
DE60029195T2 (de)	1999-02-22	2007-06-28	Transgene S.A.	Verfahren zur Gewinnung von purifizierter Virenzusammensetzung
US6783939B2 (en) *	2000-07-07	2004-08-31	Alphavax, Inc.	Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
WO2003014367A1 (en) *	2001-08-08	2003-02-20	The Trustees Of The University Of Pennsylvania	Method for purification of viral vectors having proteins which bind sialic acid
US7045335B2 (en) *	2001-09-06	2006-05-16	Alphavax, Inc.	Alphavirus replicon vector systems
JP4550421B2 (ja)	2001-12-12	2010-09-22	メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド	ウイルスの保存のための組成物
US20030232018A1 (en) *	2002-01-18	2003-12-18	Berlex Biosciences	Stabilized formulations of adenovirus
US20030224354A1 (en) *	2002-05-30	2003-12-04	Introgen Therapeutics Inc.	Quantifying viral particles with intrinsic fluorescence
EP1371723A1 (en) *	2002-06-12	2003-12-17	Procorde GmbH	Process for preparing an adenovirus-containing preparation
CA2496918A1 (en) *	2002-08-28	2004-03-11	Introgen Therapeutics Inc.	Chromatographic methods for adenovirus purification
WO2004055167A2 (en) *	2002-12-13	2004-07-01	Alphavax, Inc.	Alphavirus particles and methods for preparation
DK1585812T3 (en)	2002-12-13	2017-04-10	Alphavax Inc	MULTI-ANTI-ANTI-ANTI-VIRUS REPLICATE PARTICLES AND PROCEDURES
KR101518309B1 (ko) *	2003-03-20	2015-05-08	알파벡스, 인크.	개선된 알파바이러스 레플리콘 및 헬퍼 구축물
US20040229335A1 (en)	2003-05-15	2004-11-18	Introgen Therapeutics, Inc.	Methods and compositions for the production of adenoviral vectors
WO2004112707A2 (en) *	2003-06-18	2004-12-29	Onyx Pharmaceuticals, Inc.	Method for purifying virus
US7419674B2 (en) *	2003-07-11	2008-09-02	Alpha Vax, Inc.	Alpha virus-based cytomegalovirus vaccines
EP1944318B1 (en)	2003-07-21	2011-03-02	Transgene S.A.	Multifunctional cytokines
WO2005080556A2 (en) *	2004-02-23	2005-09-01	Crucell Holland B.V.	Virus purification methods
EP1751289B1 (en) *	2004-05-18	2009-01-14	Alphavax, Inc.	Tc-83-derived alphavirus vectors, particles and methods
JP2008518632A (ja)	2004-11-03	2008-06-05	イントロゲンセラピューティックス，インコーポレイテッド	アデノウイルスベクターの製造および精製のための新規方法
WO2006057876A2 (en) *	2004-11-22	2006-06-01	Cedars-Sinai Medical Center	Methods and solutions for tissue preservation
BRPI0609695A2 (pt)	2005-03-21	2011-10-18	Applera Corp	composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para tratar uma doença e uma paciente sofrendo uma terapia
CA2602944C (en) *	2005-04-11	2015-08-11	Crucell Holland B.V.	Virus purification using ultrafiltration
WO2008089448A2 (en)	2007-01-19	2008-07-24	Cornell Presearch Foundation, Inc.	Methods and compositions for promoting survival & proliferation of endothelial cells & stimulating angiogenesis
AR065076A1 (es)	2007-01-30	2009-05-13	Transgene Sa	Vacuna contra el papilomavirus
EP2183368B1 (en) *	2007-06-21	2016-08-10	Alphavax, Inc.	Promoterless cassettes for expression of alphavirus structural proteins
EA019928B1 (ru)	2008-11-03	2014-07-30	Круселл Холланд Б.В.	Способ получения аденовирусных векторов
US9393299B2 (en)	2009-08-07	2016-07-19	Transgene S.A.	Composition for treating HBV infection
MX2012004221A (es)	2009-10-15	2012-06-08	Crucell Holland Bv	Proceso para purificacion de adenovirus de cultivos de alta densidad celular.
WO2011045378A1 (en)	2009-10-15	2011-04-21	Crucell Holland B.V.	Method for the purification of adenovirus particles
BR112012019023B1 (pt)	2010-02-15	2021-12-21	Janssen Vaccines & Prevention B.V.	Método para produzir adenovírus recombinante sorotipo 26 (rad26), e, uso de um biorreator
JP2013523175A (ja)	2010-04-14	2013-06-17	イーエムディー・ミリポア・コーポレーション	高力価、高純度のウイルスストックの作製方法及びその使用方法
BR112013014457A8 (pt)	2010-12-09	2017-12-19	Pasteur Institut	usos da enzima 6-metilguanina-dna-metiltrasferase (mgmt, ec 2.1.1.63) para aumentar a produção de proteína heteróloga, bem como vetor de expressão, células recombinantes e polipeptídeo de fusão compreendendo sinal de secreção peptídica e proteína snap
TWI575070B (zh)	2011-07-12	2017-03-21	傳斯堅公司	Ｈｂｖ聚合酶突變體
WO2013045668A2 (en)	2011-09-29	2013-04-04	Transgene Sa	Immunotherapy composition and regimen for treating hepatitis c virus infection
TW201318637A (zh)	2011-09-29	2013-05-16	Transgene Sa	免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
HUE027839T2 (en)	2012-03-12	2016-11-28	Crucell Holland Bv	Recombinant adenoviruses with altered terminals
NZ630753A (en)	2012-03-22	2016-12-23	Janssen Vaccines & Prevention Bv	Vaccine against rsv
US9125870B2 (en)	2012-03-22	2015-09-08	Crucell Holland B.V.	Vaccine against RSV
AU2013271338B2 (en)	2012-06-05	2018-05-24	The Australian National University	Vaccination with interleukin-4 antagonists
WO2014066443A1 (en)	2012-10-23	2014-05-01	Emory University	Gm-csf and il-4 conjugates, compositions, and methods related thereto
SG11201506624SA (en) *	2013-02-28	2015-09-29	Psioxus Therapuetics Ltd	A process for the production of adenovirus
KR102089121B1 (ko)	2013-03-14	2020-03-13	더 솔크 인스티튜트 포 바이올로지칼 스터디즈	종양살상형 아데노바이러스 조성물
DK2988780T3 (en)	2013-04-25	2019-04-08	Janssen Vaccines & Prevention Bv	STABILIZED SOLVEN RSV-F PREFUSION POLYPTIDES
CA2914792C (en)	2013-06-17	2024-02-27	Crucell Holland B.V.	Stabilized soluble pre-fusion rsv f polypeptides
GB201415579D0 (en) *	2014-09-03	2014-10-15	Psioxus Therapeutics Ltd	A process
US10947500B2 (en) *	2014-06-27	2021-03-16	Angiocrine Bioscience, Inc.	Neural cells expressing adenovirus E4ORF1, and methods of making and using the same
SG11201701502VA (en) *	2014-08-27	2017-03-30	Psioxus Therapeutics Ltd	A process for the production of adenovirus
EP4043021A3 (en)	2014-09-24	2022-11-23	Salk Institute for Biological Studies	Oncolytic tumor viruses and methods of use
SG11201704919SA (en)	2015-01-13	2017-07-28	Alfa Wassermann Inc	Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav)
WO2016128542A1 (en)	2015-02-13	2016-08-18	Transgene Sa	Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en)	2015-02-20	2016-08-25	Transgene Sa	Combination product with autophagy modulator
CA2981841A1 (en)	2015-04-14	2016-10-20	Janssen Vaccines & Prevention B.V.	Recombinant adenovirus expressing two transgenes with a bidirectional promoter
EP3821906A1 (en)	2015-07-07	2021-05-19	Janssen Vaccines & Prevention B.V.	Vaccine against rsv comprising modified f polypeptide
US10457708B2 (en)	2015-07-07	2019-10-29	Janssen Vaccines & Prevention B.V.	Stabilized soluble pre-fusion RSV F polypeptides
CA3013639A1 (en)	2016-02-23	2017-08-31	Salk Institute For Biological Studies	Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
JP7054527B2 (ja) *	2016-02-23	2022-04-14	ソークインスティテュートフォーバイオロジカルスタディーズ	アデノウイルスの複製動態を測定するための高スループットアッセイ
MA52910A (fr)	2016-04-05	2021-04-21	Janssen Vaccines & Prevention Bv	Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'un infection vrs
WO2017174564A1 (en)	2016-04-05	2017-10-12	Janssen Vaccines & Prevention B.V.	Vaccine against rsv
US20190134190A1 (en)	2016-05-04	2019-05-09	Transgene Sa	Combination therapy with cpg tlr9 ligand
BR112018072865A2 (pt)	2016-05-12	2019-04-30	Janssen Vaccines & Prevention B.V.	promotor bidirecional potente e equilibrado
EP3464331B1 (en)	2016-05-30	2020-10-28	Janssen Vaccines & Prevention B.V.	Stabilized pre-fusion rsv f proteins
JP6683847B2 (ja)	2016-06-20	2020-04-22	ヤンセンファッシンズアンドプリベンションベーフェーＪａｎｓｓｅｎＶａｃｃｉｎｅｓ＆ＰｒｅｖｅｎｔｉｏｎＢ．Ｖ．	強力でバランスのとれた双方向性プロモーター
JP7229151B2 (ja)	2016-07-14	2023-02-27	ヤンセンファッシンズアンドプリベンションベーフェー	Ｈｐｖワクチン
EP3522920A2 (en)	2016-10-10	2019-08-14	Transgene SA	Immunotherapeutic product and mdsc modulator combination therapy
US11826423B2 (en)	2016-11-16	2023-11-28	Immunomic Therapeutics, Inc.	Nucleic acids for treatment of allergies
CN110062630A (zh)	2016-12-12	2019-07-26	萨克生物研究学院	肿瘤靶向合成腺病毒及其用途
CA3053212C (en)	2017-02-09	2021-04-13	Janssen Vaccines & Prevention B.V.	Potent and short promoter for expression of heterologous genes
EP4512477A3 (en)	2017-04-22	2025-06-11	Immunomic Therapeutics, Inc.	Improved lamp constructs
BR112019023014A2 (pt)	2017-05-02	2020-05-19	Immunomic Therapeutics Inc	constructos de lamp aperfeiçoados compreendendo antígenos de câncer
CA3061278A1 (en)	2017-05-17	2018-11-22	Janssen Vaccines & Prevention B.V.	Methods and compositions for inducing protective immunity against rsv infection
CA3073790A1 (en)	2017-09-15	2019-03-21	Janssen Vaccines & Prevention B.V.	Method for the safe induction of immunity against rsv
MX2020010499A (es)	2018-04-09	2020-10-28	Salk Inst For Biological Studi	Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion.
US12398195B2 (en)	2018-05-15	2025-08-26	Immunomic Therapeutics, Inc.	Lamp constructs comprising allergens
MX2021003303A (es)	2018-09-21	2021-06-23	Univ Connecticut	Composiciones y metodos para restaurar la expresion del gen ube3a paterno en sindrome de angelman humano.
EP3880243A1 (en)	2018-11-13	2021-09-22	Janssen Vaccines & Prevention B.V.	Stabilized pre-fusion rsv f proteins
TWI852977B (zh)	2019-01-10	2024-08-21	美商健生生物科技公司	前列腺新抗原及其用途
WO2020172509A1 (en)	2019-02-21	2020-08-27	Unleash Immuno Oncolytics, Inc.	Oncolytic adenoviral vector and methods of use
CN121203032A (zh)	2019-10-18	2025-12-26	免疫治疗有限公司	包含癌抗原的改良lamp构建物
KR20220115569A (ko)	2019-11-18	2022-08-17	얀센 바이오테크 인코포레이티드	돌연변이 calr 및 jak2에 기반한 백신 및 이의 용도
TW202144389A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在卵巢癌中表現之新抗原及其用途
WO2021209897A1 (en)	2020-04-13	2021-10-21	Janssen Biotech, Inc.	Psma and steap1 vaccines and their uses
WO2022009049A1 (en)	2020-07-06	2022-01-13	Janssen Biotech, Inc.	Prostate neoantigens and their uses
WO2022009052A2 (en)	2020-07-06	2022-01-13	Janssen Biotech, Inc.	Prostate neoantigens and their uses
US20230035403A1 (en)	2020-07-06	2023-02-02	Janssen Biotech, Inc.	Method For Determining Responsiveness To Prostate Cancer Treatment
JP2025513022A (ja)	2022-04-10	2025-04-22	イミュノミックセラピューティックス，インコーポレイテッド	免疫応答増強遺伝子を含むバイシストロニックｌａｍｐ構築物およびその使用方法
WO2025158316A1 (en)	2024-01-26	2025-07-31	Janssen Biotech, Inc.	Ovarian neoantigens and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5173418A (en) *	1985-05-10	1992-12-22	Benzon Pharma, A/S	Production in Escherichia coli of extracellular Serratia spp. hydrolases
FR2705686B1 (fr) *	1993-05-28	1995-08-18	Transgene Sa	Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
WO1995019427A1 (en)	1994-01-12	1995-07-20	Genetic Therapy, Inc.	Purification of retroviral vectors
FR2716893B1 (fr)	1994-03-03	1996-04-12	Rhone Poulenc Rorer Sa	Virus recombinants, leur préparation et leur utilisation thérapeutique.
ATE189697T1 (de)	1994-03-22	2000-02-15	Immune Response Corp Inc	Die hocheffiziente herstellung und isolierung von viruspartikeln
US5837520A (en) *	1995-03-07	1998-11-17	Canji, Inc.	Method of purification of viral vectors
BR9710030A (pt) *	1996-07-01	1999-08-10	Rhone Poulenc Rorer Sa	Processo de produção de adenovírus recombinantes processo de purificação de adenovírus recombinantes a partir de um meio biológico preparação viral purificada composição farmacêutica e utilização de iodixanol-5,5'-[(2-Hidroxipropil-1,3-Propanottl)-Bis[N,N'-Bis(2,3-Didroxipropil-2,4,6-Triodo-1,3-Benzenocarboxamida]
JP4492826B2 (ja)	1996-11-20	2010-06-30	イントロジェンセラピューティクス，インコーポレイテッド	アデノウイルスベクターの産生および精製のための改良された方法
US6261823B1 (en) *	1996-12-13	2001-07-17	Schering Corporation	Methods for purifying viruses
PL349074A1 (en) *	1998-12-31	2002-07-01	Aventis Pharma Sa	Method for separating viral particles

1997
- 1997-06-20 BR BR9710030A patent/BR9710030A/pt not_active Application Discontinuation
- 1997-06-20 SK SK1810-98A patent/SK181098A3/sk unknown
- 1997-06-20 KR KR1020057007148A patent/KR20050043996A/ko not_active Abandoned
- 1997-06-20 US US09/202,545 patent/US6485958B2/en not_active Expired - Fee Related
- 1997-06-20 EP EP97930560A patent/EP0944717A1/fr not_active Ceased
- 1997-06-20 CA CA002258158A patent/CA2258158A1/fr not_active Abandoned
- 1997-06-20 HU HU0001271A patent/HU224558B1/hu not_active IP Right Cessation
- 1997-06-20 AU AU34470/97A patent/AU3447097A/en not_active Abandoned
- 1997-06-20 IL IL12769297A patent/IL127692A0/xx unknown
- 1997-06-20 CZ CZ984383A patent/CZ438398A3/cs unknown
- 1997-06-20 JP JP10503872A patent/JP2000514290A/ja not_active Ceased
- 1997-06-20 WO PCT/FR1997/001107 patent/WO1998000524A1/fr not_active Ceased
1998
- 1998-12-30 NO NO986202A patent/NO986202L/no not_active Application Discontinuation
2002
- 2002-10-10 US US10/267,865 patent/US6905862B2/en not_active Expired - Fee Related
2005
- 2005-03-23 US US11/086,678 patent/US20050287657A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2258158A1 (fr)	1998-01-08
KR20050043996A (ko)	2005-05-11
HUP0001271A3 (en)	2002-01-28
CZ438398A3 (cs)	1999-03-17
US6905862B2 (en)	2005-06-14
EP0944717A1 (fr)	1999-09-29
IL127692A0 (en)	1999-10-28
NO986202D0 (no)	1998-12-30
US20020028497A1 (en)	2002-03-07
HU224558B1 (hu)	2005-10-28
HUP0001271A1 (hu)	2000-08-28
SK181098A3 (en)	1999-07-12
NO986202L (no)	1999-02-15
AU3447097A (en)	1998-01-21
US20030143730A1 (en)	2003-07-31
JP2000514290A (ja)	2000-10-31
US20050287657A1 (en)	2005-12-29
US6485958B2 (en)	2002-11-26
WO1998000524A1 (fr)	1998-01-08

Publication	Publication Date	Title
BR9710030A (pt)	1999-08-10	Processo de produção de adenovírus recombinantes processo de purificação de adenovírus recombinantes a partir de um meio biológico preparação viral purificada composição farmacêutica e utilização de iodixanol-5,5'-[(2-Hidroxipropil-1,3-Propanottl)-Bis[N,N'-Bis(2,3-Didroxipropil-2,4,6-Triodo-1,3-Benzenocarboxamida]
LU91314I2 (fr)	2007-04-23	"Combinaison de particules viroides de papillomavirus humain de type 6, 11, 16 et 18 (GARDASIL -GilGARD )"
EP1005562A4 (en)	2002-05-22	Succinic acid production and purification
DE69721840D1 (en)	2003-06-12	Zuckerrohr bacilliformviruspromotor
DK0386734T3 (da)	1996-02-05	Immunogene regioner på E-7-proteinet af humant papillomavirus type 16
IT1217658B (it)	1990-03-30	Processo perfezionato per la produzione di perfluoropolieteri costituiti sostanzialmente da unita' perfludossietilenche e perfluoroossipropileniche
BR9807618A (pt)	2000-02-15	Análogo de fator xdelta, dna recombinante codificante para um análogo de fator xdelta, células transformadas, preparação, uso da mesma, e, processos para produzir uma preparação contendo análogo de fator xdelta recombinante purificado e análogo de fator xa.
WO1996029413A3 (en)	1996-11-28	Dna encoding human papilloma virus type 18
BR9507771A (pt)	1997-08-19	Processos para preparação de ácido 1-Butil-2-(2'-(2H-Tetratozol-5-IL)-Bifenil-4-Ilmetil(-1H-Indol-3-Carboxílico
GB2287024B (en)	1998-07-08	Preparation and purification of L-5-(2-hydroxypropylamino)-2,4,6-triiodoisophthalic acid bis-(1,3-dihydroxypropylamide) contrast agent
EP0996719A4 (en)	2002-05-08	A novel nucleic acid molecule
BR9708227A (pt)	1999-07-27	Processo de purificação de dna duplo filamento de pureza farmacêutica preparação de dna plasmídico recombinante e composição farmacêutica
FI873033L (fi)	1988-01-12	Happaman fibroblastikasvutekijän nukleotidisekvenssi, plasmidi, isäntäsolu ja puhdistus
NO921580D0 (no)	1992-04-23	Soetningsmiddel utledet fra l-aspartinsyre og l-glutaminsyre og fremgansmaate ved fremstilling derav
FI963440L (fi)	1996-09-03	Uudet aminohappojohdannaiset, näiden valmistusmenetelmä ja näitä yhdisteitä sisältävät farmaseuttiset seokset
IL120483A (en)	2000-07-16	Process for the preparation of (S)-N-N'-bis¬2-hydroxy-1-hydroxymethyl)ethyl¾-5-(2-acetoxy-propionylamino)-2,4,6-triiodo-isophthalamide
PT87004A (pt)	1988-04-01	Process for the preparation of compositions for the treatment of viral infections and composites 3'-azide-2',3'-didesoxy-in osine and 3'-fluoro-2',3'-didesoxyguanosine
FI951759A7 (fi)	1995-10-15	Menetelmä 2,2-difluoriketeenisilyyli-O,S-asetaalien ja alfa, alfa-difluori-beta-silyylioksi-1,3-dioksolaani-4-propaanihapon O,S-estereiden valmistamiseksi
FR2727111B1 (fr)	1997-01-17	Nouveaux analogues soufres d'aminoacides, leur procede de preparation et leurs applications comme medicaments
IL124415A0 (en)	1998-12-06	Novel intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
IT1189070B (it)	1988-01-28	Processo per la preparazione della l(-)-carnitina cloruro a partire da esteri 3,4-epossibutirrici
FR2612186B1 (fr)	1989-07-21	Carbonyl 2,2' bis (alkyl-4 oxadiazolidines-1,2,4-diones-3,5), leur procede de preparation et leur utilisation comme intermediaires de synthese dans la preparation de carbamates
WO1996020212A3 (en)	1996-09-26	Peptide nucleic acid incorporating a chiral backbone
FI944227A0 (fi)	1994-09-13	1,2,3,4-tetrahydrokinolin-8-sulfonihapot ja -happokloridit, niiden valmistus ja käyttö synteesin välituotteina
FR2728902B1 (fr)	1997-01-31	Derives d'acide 8-oxo-5,8-dihydro-6h-dibenzo(a,g)quinolizine-13-propanoique, leur preparation et leur application en therapeutique

Legal Events

Date	Code	Title	Description
2003-07-01	TC	Change of name
2006-07-18	B25A	Requested transfer of rights approved	Owner name: GENCELL S.A. (FR) Free format text: TRANSFERIDO DE: AVENTIS PHARMA S.A.
2006-08-01	B25F	Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement	Owner name: GENCELL S.A. (FR) Free format text: A FIM DE ATENDER AO PEDIDO DE ALTERACAO DE NOME CONTIDO NA PETICAO NO 030277/RJ, DE 31/05/04, APRESENTE O DEVIDO DOCUMENTO DE ALTERACAO DE RAZAO SOCIAL.
2006-09-05	B25L	Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled	Owner name: GENCELL S.A. (FR) Free format text: REFERENTE A RPI 1856 COD. (25.6) DE 01/08/2006, POR TER SIDO INDEVIDO.
2006-09-19	B25D	Requested change of name of applicant approved	Owner name: GENCELL SAS (FR) Free format text: ALTERADO DE: GENCELL S.A.
2007-02-06	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2007-12-26	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: O DEPOSITANTE DEIXOU DE APRESENTAR MANIFESTACAO SOBRE O PARECER NEGATIVO, ASSIM, DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.
2009-08-18	B25D	Requested change of name of applicant approved	Owner name: CENTELION S.A.S. (FR) Free format text: ALTERADO DE: GENCELL SAS